Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.05 - Poster Session 1 - Preclinical Models of Therapeutics/Imaging
- Type: Poster Session
- Track: Biology
- Presentations: 25
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.05-007 - Large scale establishment of genetically diverse patient-derived primary tumor xenografts from resected early stage non-small cell lung cancer (NSCLC) patients
09:30 - 09:30 | Author(s): L. Kim
- Abstract
Loading...
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-028 - A Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma
09:30 - 09:30 | Author(s): S. Wang
- Abstract
Loading...
-
+
P1.22 - Poster Session 1 - Epidemiology, Etiology
- Type: Poster Session
- Track: Prevention & Epidemiology
- Presentations: 12
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.22-005 - A Prospective, Molecular Epidemiological Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer with Adenocarcinoma Histology (PIONEER study) - China Subset Analysis
09:30 - 09:30 | Author(s): Y. Shi
- Abstract
Loading...
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-021 - Interim outcome analysis of phase II study of neoadjuvant bevacizumab plus pemetrexed and carboplatin in unresectable, locally advanced lung adenocarcinoma
09:30 - 09:30 | Author(s): N. Li
- Abstract
Loading...
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-005 - Randomized, open-label, multi-center study of Gefitinib dose-escalation (500mg/d versus 250mg/d) in advanced NSCLC patient achieved Stable Disease (SD) after one-month Gefitinib treatment
09:30 - 09:30 | Author(s): L. Zhang
- Abstract
Loading...
-
+
MO20 - Preclinical Therapeutic Models II
- Type: Mini Oral Abstract Session
- Track: Biology
- Presentations: 10
- Moderators:P. Waring
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Gallery B, Level 1
-
+
MO20.02 - Proteomic analysis identifies baseline PI3K/Akt pathway activation and treatment-induced supppression of mTOR signaling as determinants of response to MEK inhibition
10:35 - 10:40 | Author(s): K.A. Gold
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
